Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through. Fair value range: low $225, high $370, with mid-point at $297.
Bu rapor henüz çevrilmedi. Çeviri kuyruğu yetiştiğinde birkaç dakika sonra sayfayı yenileyin.
§1 Yönetici özeti
Stryker benefits from high switching costs and Mako ecosystem lock-in.
Fair value mid-point of $297.38 implies only 1% upside, prompting a Hold.
Trades at a massive premium to peers (PEG 2.51), posing severe multiple contraction risk if growth slows.
Watch Mako placement volumes and 20.5% operating margin stability.
Fair value
$297
Margin of safety
+1.0%
Confidence
88/100
Moat
9/10
Educational research only - not investment advice, an offer, or a trade instruction. Confirm current data and do your own due diligence before acting.
$294.45Price
Low $225.47
Mid $297.38
High $370.47
Stryker is a high-quality mature compounder with a durable moat derived from high switching costs, scale economies, and deep hospital relationships across MedSurg and Orthopaedics. The continued adoption of Mako robotics provides a strong catalyst for market share gains and implant pull-through.
High switching costs in hospital
High switching costs in hospital ecosystems
Scale economies in MedSurg and
Scale economies in MedSurg and Orthopaedics
Cycle upside
Accelerating hospital capital expenditures and aging demographics driving elective procedure volumes.
SYK (SYK)'s intrinsic value is triangulated from discounted earnings at two cost-of-equity levels (strict CAPM with raw beta, moderate with adjusted beta), with owner earnings used as a floor for high-growth names.
Each model produces a per-share value; the composite range comes from a weighted blend driven by the archetype's model-applicability matrix. Cost of equity, terminal growth, and the deceleration curve are documented in the assumption ledger.
EPS-based models are discounted at cost of equity; FCFF models use WACC and then subtract net debt to bridge enterprise value to equity value. Each model is labelled with its discount-rate convention so the reader can verify the bridge.
Owner earnings (Buffett's definition) is net income plus depreciation and amortization minus maintenance capex. We do not subtract stock-based compensation again because net income already includes it; dilution is tracked separately via share-count growth.
FAQ
SYK — frequently asked questions
Based on our latest analysis, SYK trades close to fair value. The current price is $294 versus a composite fair-value midpoint of $297 (range $225–$370), which implies roughly 1.0% upside to the midpoint.
Our composite fair-value range for SYK is $225–$370, with a midpoint of $297. The range is triangulated across multiple valuation models (discounted earnings, forward earnings scenarios, peer multiples, and where applicable owner earnings or reverse DCF) and weighted by reliability for SYK's archetype.
Our current rating for SYK is Hold with a confidence score of 88/100. Hold. Current price ($294.45) is near our composite mid-point ($297.38) with balanced upside/downside risk. This is research for educational purposes, not personalized investment advice.
The top risks our latest report flags for SYK are: Multiple Contraction to Peer Median; Orthopaedic Pricing Collapse; Robotics CapEx Freeze. The single biggest risk is Multiple Contraction to Peer Median: SYK's PEG of 2.51 compresses to the med-tech peer median of 1.56 as Mako-driven growth normalizes.
Our current rating for SYK is Hold, issued with a confidence score of 88/100 and a moat score of 9/10. The rating reflects the composite fair-value range ($225–$370) versus the current price of $294.
SYK is classified as a mature compounder stock. Archetype determines how every downstream parameter — discount rate, terminal growth, deceleration curve, terminal multiple, scenario probability weights, scorecard weights, and which valuation models are prioritized — is calibrated for SYK.
